Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Janssen Pharmaceuticals has acquired the selective kappa opioid receptor antagonist CERC-501 from Cerecor for $25 million plus a possible $20 million milestone payment. Baltimore-based Cerecor acquired CERC-501 from Eli Lilly & Co. in early 2015 and was developing the drug as a treatment for depression and substance use disorders. Late last year, Cerecor announced that CERC-501 failed in a trial as a treatment for nicotine withdrawal.
This article has been sent to the following recipient: